Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma
{{output}}
Establishing a strategy for sequencing of T cell redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunological impact of bispecific T cell engaging antibodies (BsAb) ... ...
